A phase 1 study of K-912, nonrandomized, open label, dose escalation study in Japanese patients with solid tumors.

Trial Profile

A phase 1 study of K-912, nonrandomized, open label, dose escalation study in Japanese patients with solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Epirubicin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Kowa
  • Most Recent Events

    • 04 Jan 2017 Results published in the Investigational New Drugs
    • 17 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top